Charles River Laboratories International, Inc. (CRL)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 29, 2025	Dec 28, 2024	Dec 30, 2023	Dec 31, 2022	Dec 25, 2021	Dec 26, 2020
Net Income	-19.66	22.2	474.62	486.23	390.98	364.3
Depreciation & Amortization	351.85	352.34	314.12	303.87	265.54	234.92
Loss (Gain) From Sale of Assets	-3.38	0.66	0.96	-123.41	-25.03	-
Asset Writedown & Restructuring Costs	316.87	276.23	41.91	5.82	0.73	-
Loss (Gain) on Equity Investments	29.16	12.91	-97.83	26.78	30.42	-100.86
Stock-Based Compensation	66.29	69.89	72.05	73.62	71.47	56.34
Provision & Write-off of Bad Debts	15.94	14.77	18.23	6.71	1.66	6.38
Other Operating Activities	0.26	15.9	-37.79	-7.41	-17.92	11.77
Change in Accounts Receivable	9.54	21.61	-33.43	-150.57	-26.63	-85.63
Change in Inventory	-10.68	16.8	-62.3	-78.52	-25.16	-18.38
Change in Accounts Payable	19.52	-14.27	-20.43	-2.65	44.9	0.75
Change in Unearned Revenue	6.98	25.13	-37.31	88.12	3.52	37.6
Change in Other Net Operating Assets	-6.32	-79.6	51.09	-8.92	46.31	39.38
Operating Cash Flow	776.39	734.58	683.9	619.64	760.8	546.58
Operating Cash Flow Growth	10.22%	7.41%	10.37%	-18.55%	39.19%	13.65%
Capital Expenditures	-213.15	-232.97	-318.53	-324.73	-228.77	-166.56
Cash Acquisitions	-5.48	-5.48	-194.79	-283.39	-1,293	-418.63
Divestitures	17.44	-	-	163.28	122.69	-
Investment in Securities	-8.52	-11.19	-47.55	-153.73	-39.02	-15.29
Other Investing Activities	4.94	4.55	-2.29	-9.35	0.26	-1.07
Investing Cash Flow	-204.77	-245.09	-563.16	-607.92	-1,438	-601.54
Long-Term Debt Issued	-	1,082	776.35	2,952	6,951	2,231
Long-Term Debt Repaid	-	-1,494	-851.68	-2,933	-6,243	-2,200
Net Debt Issued (Repaid)	-153.64	-412.19	-75.32	19.79	708.24	30.59
Issuance of Common Stock	2.37	23.88	25.6	25.11	45.65	46.59
Repurchase of Common Stock	-462.96	-119.18	-24.16	-38.65	-40.71	-23.98
Other Financing Activities	-60.37	-43.44	-11.64	-48.65	-40.58	-5.95
Financing Cash Flow	-674.6	-550.93	-85.52	-42.4	672.6	47.25
Foreign Exchange Rate Adjustments	-3.82	-17.47	8.04	25.58	17.73	0.79
Net Cash Flow	-106.81	-78.91	43.27	-5.1	13.2	-6.93
Free Cash Flow	563.24	501.61	365.37	294.91	532.03	380.02
Free Cash Flow Growth	36.18%	37.29%	23.89%	-44.57%	40.00%	11.63%
Free Cash Flow Margin	14.00%	12.38%	8.85%	7.42%	15.03%	13.00%
Free Cash Flow Per Share	11.00	9.72	7.10	5.75	10.35	7.51
Cash Interest Paid	114.28	123.45	132.1	100.75	70.78	72.46
Cash Income Tax Paid	124.66	126.06	90.37	75.91	75.44	60.06
Levered Free Cash Flow	625.62	517.33	216.02	303.66	629.6	269.38
Unlevered Free Cash Flow	700.1	596.26	301.46	340.72	675.8	323.4
Change in Net Working Capital	-159.55	-65.84	173.55	127.98	-171.06	75.73

Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q